Antifungal & Antimicrobial Topical Patents: Top Companies, Trends 2026
Antifungal and Antimicrobial Topical Patents: Who Leads and Where the Field Is Heading
Filing has cooled from its 2018 peak. 88 filings that year against 60 in 2021 and 45 in 2024 — a 25% decline over that three-year span, though 2025-26 figures are still filling in. Annual filings ran from 81 in 2017 to a peak of 88 in 2018, then eased to 60 by 2021 and 45 by 2024 — a 25% decline over that three-year window. 2025 and 2026 figures (down to 18 so far) are undercounts still in the publication pipeline, not evidence of a further collapse.
- 1ANACOR PHARMACEUTICALS LLC8.4%
- 2POLICHEM SA5.9%
- 3NOVABIOTICS LTD4.5%
- 4BLUEBERRY THERAPEUTICS2.9%
- 5VYOME THERAPEUTICS LTD2.3%
See the full antifungal and antimicrobial topicals analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Frequently asked questions
Who are the leading patent holders in antifungal and antimicrobial topical treatments?
The ranking covers 100 companies across 1,730 records in scope, with the leading assignee holding 146 records. However, concentration at the top is limited: the top 5 assignees combined account for only 24.0% of all records, and the top 10 for 35.0%, meaning there is a substantial long tail of smaller filers rather than a small group of dominant players. This makes the field more open to new entrants than the leader’s individual count might suggest.
Has patent filing in this space been growing or slowing down?
Filings peaked in 2018 at 88 in a given year, then declined to 60 by 2021 and 45 by 2024 — a 25% drop over that three-year span. Figures for 2025 and 2026 appear lower still, but publication typically lags actual filing by around 18 months, so those most recent years are undercounts rather than proof of a further slowdown. The honest read is a field that has cooled from its 2018 peak but has not yet shown its true 2025-26 trajectory.
What patent classes cover the most antifungal and antimicrobial topical claims?
A61K (medicinal preparations) is by far the most common class, appearing on 87.5% of the 1,730 records in scope. A61P (therapeutic activity of compounds) follows at 45.2%, and A61Q (cosmetics use) at 13.5%. Because a single record can carry multiple IPC classes, these shares add up to more than 100% and should not be read as mutually exclusive categories.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Antifungal and Antimicrobial Topicals covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.